

## **Digestome Therapeutics Completes \$10 Million Seed Financing**

**SAN FRANCISCO, CA, January 6, 2022** – Digestome Therapeutics, a biotech company developing first-in-class therapeutics that stimulate mind via the gut-brain-axis, announced today the completion of a \$10M Seed financing to advance its lead program into clinical trials starting early 2022.

Digestome is building its clinical hypothesis upon VNS (vagus nerve stimulation), which has been clinically validated and FDA approved in epilepsy and depression, and is in trials for other psychiatric, neurodegenerative and inflammatory diseases. However, the products are medical devices with limitations (e.g., invasiveness) and are not first-line options. Digestome's first-in-class therapeutics also affect the brain via the vagus nerve, but are daily, oral drugs with a unique safety profile due to being gut-acting, and gut-restricted (no systemic exposure). The lead program, DGX-001, will enter a first-in-human proof of mechanism study in early 2022.

“This financing allows Digestome to advance DGX-001 into clinical trials, an exciting opportunity to demonstrate the safety and potential activity of our first-in-class, gut-brain-axis therapeutics,” said Ken Horne, President of Digestome. “We are excited to develop DGX-001 for negative symptoms and cognitive impairment in schizophrenia patients, as well as non-motor symptoms in Parkinson’s Disease patients. Both indications represent a very high unmet need in psychiatry, neurology and movement disorders,” said Igor Grachev, MD, PhD, Chief Medical Officer. “Over 60% of schizophrenia patients have clinically significant negative symptoms, and over 70% of Parkinson’s patients have clinically significant non-motor symptoms. In both cases, there are no approved therapies and these patients’ symptoms go largely untreated. DGX-001’s unique pharmacology and mechanism of action are particularly well suited for these indications.”

The financing was led by Remiges Ventures, with participation from ANRI, Zhongze Pharma, Kyoto iCap and Miyako Capital.

About Digestome:

[www.digestometx.com](http://www.digestometx.com)

Contact:

[info@digestometx.com](mailto:info@digestometx.com)